RxDoctor Payments Data

Blanca Vazquez, MD

Neurology · New York, NYNPI 1255449716

Payments from drug & device makers

$357,049in general payments, 2019–2025

Across 150 payments — averaging $2380.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$136K
  • UCB SA$102K
  • Neurelis, Inc.$55K
  • UCB Biosciences Inc.$33K
  • UCB, Inc.$27K
  • Aquestive Therapeutics, Inc.$2K
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$6,17621%
  • Speaking & faculty fees$17,23559%
  • Travel & lodging$3,18411%
  • Food & beverage$2,3748%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357,049 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$96,428
Medicare patients
228
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate402$585,606
BriviactBrivaracetam181$334,285
AptiomEslicarbazepine Acetate67$187,356
TopamaxTopiramate36$107,793
KeppraLevetiracetam57$95,223
FycompaPerampanel69$86,484
EpidiolexCannabidiol (Cbd)14$73,249
VimpatLacosamide58$64,149
LamictalLamotrigine33$58,155
OnfiClobazam17$57,787
Lamotrigine ErLamotrigine156$55,155
Lacosamide387$54,859
Oxtellar XrOxcarbazepine13$26,437
ValtocoDiazepam22$23,201
Clobazam101$22,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$136,488$585,606402 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$26,863$418,067255 claims
Sunovion Pharmaceuticals Inc.Aptiom$964$187,35667 claims
UCB SAKeppra$101,580$95,22357 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$28$26,43713 claims
Neurelis, Inc.Valtoco$54,700$23,20122 claims
AbbVieNamzaric$19$7,60512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →